EG Stock Analysis: Everest | NYSE
Insurance - Reinsurance | NYSE, USA | Market Cap: 14.479m USD | 12M Return: 11.2% | BMG3223R1088 | Charts, Fundamentals & Technical Analysis
Avg Turnover: 98.6M
EPS Trend: -40.1%
Qual. Beats: 0
Rev. Trend: 84.3%
Qual. Beats: 8
Warnings
No concerns identified
Tailwinds
No distinct edge detected
Seasonality 11.6 years of data
How good or bad each month usually is (without trend). The score below shows how much you can trust it: 0 = pure chance, >40 gets interesting and >55 is strong.
Everest Group, Ltd. (NYSE: EG) is a Bermuda-domiciled provider of reinsurance and insurance products operating through two main segments: Insurance and Reinsurance. The company distributes its offerings globally across the United States, Europe, and other international markets, using a mix of direct relationships with ceding companies, reinsurance brokers, wholesale and retail brokers, surplus lines brokers, general agents, and program administrators.
Its product portfolio spans a broad range of property and casualty coverages, including specialty lines such as mortgage, catastrophe, marine, aviation, engineering, professional liability, credit and surety, motor, agriculture/crop, and political violence reinsurance. The company was founded in 1973 and is headquartered in Hamilton, Bermuda, a jurisdiction long favored as a hub for global re/insurers due to its specialized regulatory framework and capital efficiency for underwriting risk.
Originally known as Everest Re Group, Ltd., the company rebranded to Everest Group, Ltd. in July 2023 to reflect its broader dual-segment structure spanning both reinsurance and primary insurance. As a large-cap stock within the Financials sector, Everest participates in the reinsurance sub-industry, where firms assume portions of underwriting risk from primary insurers in exchange for premiums, often providing capacity for catastrophic and specialty exposures that primary carriers seek to offload.
- Reinsurance pricing hardens as cat losses drive rate increases
- Higher investment income boosts margins as interest rates rise
- Insurance segment expansion diversifies revenue mix beyond reinsurance
- Catastrophe losses from hurricanes and wildfires pressure combined ratio
| Net Income: 1.91b TTM > 0 and > 6% of Revenue |
| FCF/TA: 0.03 > 0.02 and ΔFCF/TA -4.15 > 1.0 |
| NWC/Revenue: -153.0% < 20% (prev -56.45%; Δ -96.56% < -1%) |
| CFO/TA 0.03 > 3% & CFO 2.07b > Net Income 1.91b |
| Net Debt (38.2m) to EBITDA (2.57b): 0.01 < 3 |
| Current Ratio: 0.40 > 1.5 & < 3 |
| Outstanding Shares: last quarter (40.3m) vs 12m ago -4.62% < -2% |
| Gross Margin: 28.79% > 18% (prev 11.16%; Δ 17.63% > 0.5%) |
| Asset Turnover: 27.23% > 50% (prev 28.93%; Δ -1.70% > 0%) |
| Interest Coverage Ratio: 19.04 > 6 (EBIT TTM 2.57b / Interest Expense TTM 135.0m) |
| A: -0.41 (Total Current Assets 16.8b - Total Current Liabilities 42.4b) / Total Assets 62.2b |
| B: 0.28 (Retained Earnings 17.6b / Total Assets 62.2b) |
| C: 0.04 (EBIT TTM 2.57b / Avg Total Assets 61.3b) |
| D: 0.33 (Book Value of Equity 15.4b / Total Liabilities 46.7b) |
| Altman-Z'' = -1.14 = CCC |
As of September 01, 2026, the stock is trading at USD 374.65 with a total of 452,583 shares traded. Over the past week, the price has changed by -0.57%, over one month by +0.13%, over three months by +16.02% and over the past year by +11.16%.
Current recommended Stop Loss: 357.30 (which is 4.6% or 2.3 ATR below the current price).
Everest has received a consensus analysts rating of 3.75. Therefore, it is recommended to hold EG.
- StrongBuy: 3
- Buy: 3
- Hold: 6
- Sell: 0
- StrongSell: 0
| Analysts Target Price | 408.5 | 9% |
P/E Trailing = 7.9816
P/E Forward = 5.4765
P/S = 0.8605
P/B = 0.9385
P/EG = 0.9682
Revenue TTM = 16.7b USD
EBIT TTM = 2.57b USD
EBITDA TTM = 2.57b USD
Long Term Debt = 3.59b USD (from longTermDebt, last quarter)
Short Term Debt = 28.0m USD (from shortTermDebt, last fiscal year)
Debt = 3.66b USD (from shortLongTermDebtTotal, last quarter) + Leases 69.2m
Net Debt = 38.2m USD (calculated: Debt 3.66b - CCE 3.62b)
Enterprise Value = 14.5b USD (14.5b + Debt 3.66b - CCE 3.62b)
Interest Coverage Ratio = 19.04 (Ebit TTM 2.57b / Interest Expense TTM 135.0m)
EV/FCF = 7.02x (Enterprise Value 14.5b / FCF TTM 2.07b)
FCF Yield = 14.25% (FCF TTM 2.07b / Enterprise Value 14.5b)
FCF Margin = 12.38% (FCF TTM 2.07b / Revenue TTM 16.7b)
Net Margin = 11.45% (Net Income TTM 1.91b / Revenue TTM 16.7b)
Gross Margin = 28.79% ((Revenue TTM 16.7b - Cost of Revenue TTM 11.9b) / Revenue TTM)
Gross Margin QoQ = 24.67% (prev 45.50%)
Tobins Q-Ratio = 0.23 (Enterprise Value 14.5b / Total Assets 62.2b)
Interest Expense / Debt = 3.69% (Interest Expense 135.0m / Debt 3.66b)
Taxrate = 16.28% (372.0m / 2.29b)
NOPAT = 2.15b (EBIT 2.57b * (1 - 16.28%))
Current Ratio = 0.40 (Total Current Assets 16.8b / Total Current Liabilities 42.4b)
Debt / Equity = 0.24 (Debt 3.66b / totalStockholderEquity, last quarter 15.4b)
Debt / EBITDA = 0.01 (Net Debt 38.2m / EBITDA 2.57b)
Debt / FCF = 0.02 (Net Debt 38.2m / FCF TTM 2.07b)
Total Stockholder Equity = 15.4b (last 4 quarters mean from totalStockholderEquity)
RoA = 3.12% (Net Income 1.91b / Total Assets 62.2b)
RoE = 12.43% (Net Income TTM 1.91b / Total Stockholder Equity 15.4b)
RoCE = 13.54% (EBIT 2.57b / Capital Employed (Equity 15.4b + L.T.Debt 3.59b))
RoIC = 11.35% (NOPAT 2.15b / Invested Capital 19.0b)
WACC = 5.12% (E(14.5b)/V(18.1b) * Re(5.63%) + D(3.66b)/V(18.1b) * Rd(3.69%) * (1-Tc(0.16)))
Discount Rate = 5.63% (= CAPM, Blume Beta Adj.)
Shares (quarterly) Correlation: -91.36 | Cagr: -2.76%
[DCF] Terminal Value 73.10% ; FCFF base≈3.05b ; Y1≈2.68b ; Y5≈2.16b
[DCF] Fair Price = 903.9 (EV 34.7b - Net Debt 38.2m = Equity 34.7b / Shares 38.3m; r=8.35% [WACC [floored]]; 5y FCF grow -15.0% → 2.50% )
EPS Correlation: -40.07 | EPS CAGR: -23.87% | SUE: 0.07 | # QB: 0
Revenue Correlation: 84.30 | Revenue CAGR: 7.42% | SUE: 0.93 | # QB: 8
EPS current Quarter (2026-09-30): EPS=8.20 | Chg30d=-2.95% | Revisions=+15% | Analysts=13
EPS current Year (2026-12-31): EPS=53.77 | Chg30d=+2.54% | Revisions=+50% | GrowthEPS=+20.7% | GrowthRev=-20.0%
EPS next Year (2027-12-31): EPS=59.75 | Chg30d=-1.15% | Revisions=-7% | GrowthEPS=+11.1% | GrowthRev=-2.6%
[Analyst] Revisions Ratio: +23% (up=20, down=12)